Meta AnalysisID 1861
华蟾毒它灵联合化疗治疗晚期乳腺癌的有效性与安全性研究：随机对照试验Meta分析
CRD42020154411
To evaluate the efficacy and safety of cinobufotalin combined with chemotherapy for advanced breast cancer
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 1861
- Evidence Id
- 10419
- Core Evidence Id
- 10419
- Source Meta Analysis Id
- 1803
- Herb2 Meta Analysis Id
- HBMA001803
- Crd Id
- CRD42020154411
- Title
- Study on the effectiveness and safety of cinobufotalin combined with chemotherapy for advanced breast cancer: a meta-analysis of randomized controlled trials.
- Review Question
- To evaluate the efficacy and safety of cinobufotalin combined with chemotherapy for advanced breast cancer
- Study Type Included
- The experimental group was treated with cinobufotalin (unrestricted dosage form) combined with chemotherapy, while the control group was treated with the same chemotherapy regimen as the experimental group.
- Condition Being Studied
- advanced breast cancer
- Participant
- Patients with advanced breast cancer.
- Animal
- Human Disease Modelled
- Intervention
- Inclusion criteria:Interventions: The experimental group was treated with cinobufotalin (capsule, injection, tablet) combined with conventional chemotherapy; the control group was treated with conventional simple chemotherapy.
- Comparator Control
- The experimental group was treated with cinobufotalin (unrestricted dosage form) combined with chemotherapy, while the control group was treated with the same chemotherapy regimen as the experimental group.
- Main Outcome
- Outcome indicators included clinical efficacy; adverse reactions (gastrointestinal reactions, bone marrow suppression, alopecia, liver and kidney damage, peripheral neurotoxicity and so on). Measures of effect WHO criteria for evaluating the efficacy of solid tumors;WHO criteria for toxicity and side effects of cancer treatmemt.
- Outcome Measure
- Additional Outcome
- KPS score and pain relief rate. Measures of effect Assessment of pain efficacy: complete remission (CR): complete pain after treatment; partial remission (PR): pain is significantly less than before administration, sleep is basically undisturbed, can normal life; mild remission (MR): pain is less than before administration, but still feel obvious pain, sleep is disturbed; ineffective (NR): compared with before treatment, No. The pain relief rate was CR + PR. Quality of life evaluation: With Karnofsky score as the standard, KPS increased by more than 10 points after treatment was improved, the change was stable within 10 points, and decreased by less than 10 points.
- Study Method
- Meta-analysis, Systematic review
- Keyword
- Humans
- Contact
- Xu Jing [email protected]
- Organisational Affiliation
- Dongzhimen Hospital, Beijing University of Chinese Medicine
- Funding Source
- Dongzhimen Hospital, Beijing University of Chinese Medicine
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- China
- Review Stage
- Review Ongoing
- First Submission Date
- 2019-10-12
- Registration Date
- 2020-04-28
- Anticipated Start Date
- 2019-10-12
- Anticipated Completion Date
- 2021-07-31
- Title Cn
- 华蟾毒它灵联合化疗治疗晚期乳腺癌的有效性与安全性研究：随机对照试验Meta分析
- Title En
- Study on the effectiveness and safety of cinobufotalin combined with chemotherapy for advanced breast cancer: a meta-analysis of randomized controlled trials.
- Bilingual Status
- complete